nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

28.02.2023 | Gynecologic Oncology

A study of recurrence, complication and survival rates in patients with early stage vulval cancer undergoing sentinel lymph node sampling: a single-centre experience

verfasst von: Emmanouil Katsanevakis, Anuja Joshi, Zun Zhen Ong, Richard O’Connor, David Nunns, Ketankumar Gajjar

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Groin sentinel lymph node (SLN) identification and removal has become a standard of care for women with clinical early stage vulval cancer. There is evidence to support safe detection of the SLN with minimal morbidity. The purpose of this study is to report our experience of managing patients focusing on patient selection, adverse events, quality assurance of the procedure and any benefits and/or disadvantages to patients.

Methods

This was a retrospective study of patients with clinical early stage vulval cancer in a cancer centre over 5 years. Notes and hospital data were reviewed including admissions to emergency departments. Statistical software was used for the statistical analysis and the Kaplan Meier survival curve was generated to present survival rates.

Results

61 cases were analysed. A total of 156 nodes have been removed and positive nodes were identified in 14 cases. In total, 9 women (14.75%) had disease recurrence within 5 years from primary surgery. Overall, 4 patients (6.5%) developed groin recurrence. In 3 of these patients there was isolated groin recurrence (4.9%). The median length of admission was 3 days and 6 cases were managed as day cases.

Conclusions

Since the closure of the GROINNS-2 trial we have continued the procedure of SLN identification for women with clinical early stage vulval cancer. We have shown high level of adherence to our protocol and survival and complication rates comparable to other studies on the same field. There were a few patients managed as day-case which was of benefit to the patients.

Burger MPM, Hollema H, Emanuels AG, Krans M, Pras E, Bouma J (1995) The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol 57(3):327–334. https://doi.org/10.1006/gyno.1995.1151CrossRefPubMed

Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA et al (2021) Radiotherapy versus inguinofemoral lymphadenectomy as treatment for vulvar cancer patients with micrometastases in the sentinel node: results of GROINSS-V II. J Clin Oncol 39(32):3623–3632. https://doi.org/10.1200/JCO.21.00006CrossRefPubMedPubMedCentral

Van der Zee AGJ, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26(6):884–889. https://doi.org/10.1200/JCO.2007.14.0566CrossRefPubMed

Zach D, Åvall-Lundqvist E, Falconer H, Hellman K, Johansson H, Flöter RA (2021) Patterns of recurrence and survival in vulvar cancer: a nationwide population-based study. Gynecol Oncol 161(3):748–754. https://doi.org/10.1016/j.ygyno.2021.03.013CrossRefPubMed

Froeding LP, Høgdall C, Kristensen E, Zobbe V, Niemann I, Ørtoft G et al (2020) Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer—a nationwide study. Gynecol Oncol 156(1):124–130. https://doi.org/10.1016/j.ygyno.2019.10.024CrossRefPubMed

Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL et al (2012) Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol 30(31):3786–3791. https://doi.org/10.1200/JCO.2011.41.2528CrossRefPubMedPubMedCentral

Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N et al (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 107(3):dju426. https://doi.org/10.1093/jnci/dju426CrossRefPubMedPubMedCentral

Morrison J, Baldwin P, Buckley L, Cogswell L, Edey K, Faruqi A et al (2020) British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practice. Eur J Obstet Gynecol Reprod Biol 252:502–525CrossRefPubMed

Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brännström M, Landoni F et al (2017) European Society of Gynaecological Oncology Guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer 27(4):832–837CrossRefPubMed

10.

Mokhtech M, Gao SJ, Kassick M, Menderes G, Damast S (2022) Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer. Gynecol Oncol 166(1):61–68. https://doi.org/10.1016/j.ygyno.2022.05.001CrossRefPubMed

11.

Gitas G, Proppe L, Baum S, Kruggel M, Rody A, Tsolakidis D et al (2021) A risk factor analysis of complications after surgery for vulvar cancer. Arch Gynecol Obstet 304(2):511–519. https://doi.org/10.1007/s00404-020-05949-wCrossRefPubMedPubMedCentral

12.

Goker A, Guvenal T, Yanikkerem E, Turhan A, Koyuncu FM (2011) Quality of life in women with gynecologic cancer in Turkey. Asian Pac J Cancer Prev APJCP 12(11):3121–3128PubMed

13.

Rahm C, Adok C, Dahm-Kähler P, Bohlin KS (2022) Complications and risk factors in vulvar cancer surgery—a population-based study. Eur J Surg Oncol 48(6):1400–1406. https://doi.org/10.1016/j.ejso.2022.02.006CrossRefPubMed

14.

Wills A, Obermair A (2013) A review of complications associated with the surgical treatment of vulvar cancer. Gynecol Oncol 131(2):467–479. https://doi.org/10.1016/j.ygyno.2013.07.082CrossRefPubMed

15.

Mullen MM, Merfeld EC, Palisoul ML, Massad LS, Woolfolk C, Powell MA et al (2019) Wound complication rates after vulvar excisions for premalignant lesions. Obstet Gynecol 133(4):658–665. https://doi.org/10.1097/AOG.0000000000003185CrossRefPubMed

16.

Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Hu JC et al (2016) Utilization and outcomes of sentinel lymph node biopsy for vulvar cancer. Obstet Gynecol 128(4):754–760. https://doi.org/10.1097/AOG.0000000000001648CrossRefPubMedPubMedCentral

17.

Klapdor R, Hertel H, Soergel P, Hillemanns P (2017) Groin recurrences in node negative vulvar cancer patients after sole sentinel lymph node dissection. Int J Gynecol Cancer 27(1):166–170. https://doi.org/10.1097/IGC.0000000000000860CrossRefPubMed

Titel: A study of recurrence, complication and survival rates in patients with early stage vulval cancer undergoing sentinel lymph node sampling: a single-centre experience
verfasst von: Emmanouil Katsanevakis
Anuja Joshi
Zun Zhen Ong
Richard O’Connor
David Nunns
Ketankumar Gajjar
Publikationsdatum: 28.02.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2023
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-023-06968-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A study of recurrence, complication and survival rates in patients with early stage vulval cancer undergoing sentinel lymph node sampling: a single-centre experience